The funds will be used to support the advancement of Calistoga’s drug development pipeline of isoform-selective PI3K inhibitors. These include CAL-101, a delta isoform-selective PI3K inhibitor for hematologic malignancies; CAL-263, a delta isoform-selective PI3K inhibitor for treatment of inflammatory diseases; and CAL-120, a PI3K inhibitor inhibiting the delta and beta isoforms of PI3K for treatment of solid tumor malignancies.
In 2010, the company plans to advance CAL-101 and CAL-263 into Phase II clinical studies and CAL-120 into Phase I evaluation.
Carol Gallagher, CEO of Calistoga Pharmaceuticals, said: “We are pleased to have the continued support of our investors to ensure the advancement of our promising pipeline and maintain our leadership position in the development of isoform-selective PI3K inhibitors.
“We believe our compounds will provide significant benefit to patients with cancer and inflammatory diseases. We look forward to establishing clinical proof of concept for CAL-101 and CAL-263 and advancing CAL-120 into clinical evaluation.”